Статті в журналах з теми "Lung and breast"
Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Lung and breast.
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Lung and breast".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Law, Maria Y. Y., Fion W. K. Cheung, Vincent W. C. Wu, Venus W. C. Tsang, Rainnie W. Y. Kwan, Johnny Y. T. Cheng, and Fatson K. F. Wong. "An evaluation of three tangential breast irradiation techniques in Hong Kong." Journal of Radiotherapy in Practice 2, no. 1 (March 2000): 9–15. http://dx.doi.org/10.1017/s1460396900000030.
Анотація:
Background and Purpose: Loco-regional radiotherapy after breast conserving surgery significantly reduces the risk of recurrence but may induce complications in the lungs. The complications are related to the lung volume irradiated and the lung dose delivered. The purpose of this study was to evaluate three tangential breast irradiation techniques i.e. conventional technique, gantry tilting technique and half-beam block technique in terms of the percentage of irradiated lung volume and high dose lung volume for patients of different sizes.Materials and Method: Treatment planning of the three tangential breast irradiation techniques was performed using the CT scans of 20 patients with early-stage breast cancer after lumpectomy.Results: When compared with conventional technique, both half beam block technique and gantry tilting technique irradiated a significantly smaller percentage of lung volume and delivered a smaller percentage of high dose (above 30 Gy) volume in the lung. Patients with large breasts had a significantly higher percentage of lung volume irradiated to above 30Gy than those patients with small and medium breasts. The combined effect of tangential separation and technique only produced significant effect on the percentage of total lung volume irradiated but not on the high dose volume.Conclusions: Gantry tilting and half-beam block techniques can reduce a significant amount of lung volume and high dose lung volume. Half-beam block technique is recommended for small and medium breast size while for large breast size, gantry tilting technique is preferred.
2
Kusdjianto, Amanda Yuanita, Samsuri, Andri, Wijayanto Andi, Subiyantoro Agus, and Habibie Adi. "BILATERAL PNEUMOTHORAX IN LUNG METASTASES OF BREAST CARCINOMA: A CASE REPORT." International Journal of Radiology and Imaging 1, no. 01 (June 29, 2022): 18–21. http://dx.doi.org/10.21776/ub.ijri.2022.001.01.4.
Анотація:
Introduction: Bilateral pneumothorax is a rare case which happens in 1.3 to 1.9 percent of all cases of pneumothorax.1 In breast carcinoma patients, it is due to lung metastasis and first selected conservative therapy.2 Lung metastasis can be found in the appearance of pulmonary nodules called cannon-ball metastases in chest X-Ray (CXR).3 Method: Case report based on findings in chest X-Ray. Result: A 42 year-old female came to ER with sudden shortness of breath and pleuritic pain. She was diagnosed with breast carcinoma 3 years prior the ER visit and had undergone mastectomy on breasts and chemotherapy. Physical examination showed bilaterally decreased breath sounds. CXR AP postion showed bilateral pneumothorax and multiple nodules varied in size indicated lung metastases. Chest tubes with water-sealed drainage were inserted in both side of the lungs. CXR after the insertion showed reduction of the volume of pneumothorax in both side of the lungs and cannon-ball metastases in both sides of the lungs. CXR was performed serially until hospital discharge. Discussion: Bilateral pneumothorax which develops in patients who have history of breast carcinoma is considered very rare.It is caused by the metastatic process and treatment.2 CXR can be used to detect the metastasis and its complications such as pneumothorax.4 Conclusion: Bilateral pneumothorax is rarely seen in patients with breast carcinoma. Early detection of lung metastasis and appropriate therapy of tumor can prevent complications such as pneumothorax.Keywords: bilateral pneumothorax; lung metastases; breast carcinoma; chest X-Ray
3
Singh, Jarmanjeet, Hanine Inaty, Sanjay Mukhopadhyay, and Atul C. Mehta. "Chronic Pulmonary Silicone Embolism from Breast Augmentation Is Not a Common Finding in Explanted Lungs." Pulmonary Medicine 2018 (2018): 1–5. http://dx.doi.org/10.1155/2018/2987072.
Анотація:
Objective. Acute pulmonary silicone embolism (APSE) related to subcutaneous silicone injections is a well-known entity. Recently, a few cases of pathologically confirmed chronic pulmonary silicone embolism (CPSE) from breast implants have been reported. The prevalence of CPSE in women with breast augmentation is unknown. This study was done to determine the prevalence of CPSE in female lung transplant recipients with a history of breast augmentation and to determine whether breast augmentation plays a role in chronic lung diseases requiring lung transplantation. Methods. A retrospective chart review was performed to identify female lung transplant recipients with a history of breast augmentation prior to or at the time of lung transplantation. Ten patients meeting these criteria were identified. The pathologic features of the explanted lungs of these patients were reexamined for CPSE by a board-certified pathologist with expertise in lung transplantation and pulmonary embolism. Results. Of 1518 lung transplant recipients at Cleveland Clinic, 578 were females. Of 578 females, 10 (1.73%) had history of breast augmentation. A total of 84 H&E-stained slides from the explanted lungs from 10 cases were examined. No pathologic evidence of chronic silicone embolism was seen in any of the 10 cases. Conclusions. CPSE is not associated with pulmonary disease leading to lung transplantation. Breast augmentation is not a significant contributor to pulmonary disease requiring lung transplantation. Further studies are required to ascertain the prevalence of CPSE in the general breast augmentation populace and to define the relationship between breast augmentation and pulmonary disease.
4
Kuan, Emma Lo, and Steven F. Ziegler. "Thymic stromal lymphopoietin promotes interplay between breast tumor cells, neutrophils and Ly6Chi monocytes to regulate breast tumor progression." Journal of Immunology 196, no. 1_Supplement (May 1, 2016): 72.2. http://dx.doi.org/10.4049/jimmunol.196.supp.72.2.
Анотація:
Abstract Various human cancers display a T helper type 2 (Th2)-like inflammation. One possible mechanism suggested in human breast cancers is thymic stromal lymphopoietin (TSLP) secreted by breast tumor cells which can drive Th2 responses via tumor-associated dendritic cells. However, the interactions between TSLP, tumor cells, and other immune cells remain unclear. We found in breast tumor-bearing mice TSLP can also be produced by two pro-tumor myeloid cell populations, neutrophils and Ly6Chi monocytes. This non-tumor derived TSLP is crucial for both primary breast tumor growth and its metastasis to lungs. One important mechanism is myeloid derived TSLP can directly act on tumor cells and promote survival and TSLP production of tumor cells. Mice transplanted with TSLPR deficient breast tumor cells developed smaller primary breast tumors and fewer lung metastases. Conversely, mice that constitutively express TSLP in lungs transplanted with breast tumor cells had markedly increased lung metastases. Blocking TSLP in lungs resulted in a reduction in the number of lung metastases. We further discovered that TSLP signaling in Ly6Chi monocytes is crucial for their suppressor functions and their ability to differentiate into macrophages in tumors. Transfer of TSLP receptor deficient Ly6Chi monocytes significantly reduced lung metastases in tumor-bearing mice by changing T cell populations in lungs and in tumors. Our work is the first to show myeloid cell derived TSLP plays an important role in promoting breast tumor progression via maintaining tumor cell survival. We also provide a novel mechanism of the requirement of TSLP signaling in differentiation and suppressor functions in Ly6Chi monocytes.
5
Luo, Yu, Lihan Huang, Qiao Lan, Yurui Wu, Yin Li, Xiaorong Cheng, Kunhai Xiong, and Xiaoyu Wu. "Application of Deep Inspiration Breath Hold Technique in Radiotherapy After Breast- Conserving Surgery for Left Breast Cancer and Its Improvement on Cardiac Dose." Proceedings of Anticancer Research 7, no. 5 (September 25, 2023): 61–65. http://dx.doi.org/10.26689/par.v7i5.5373.
Анотація:
Objective: To analyze the application of deep inspiration breath hold technique in radiotherapy after breast-conserving surgery for left breast cancer and the improvement of cardiac dose. Methods: A total of 45 patients with left breast cancer treated in our hospital after breast-conserving surgery were selected, and the selection time was set from January 2020 to August 2022. All patients received radiotherapy. The right breast, heart, and lung volumes, and dose parameters of the heart, lungs, right breast, and left anterior descending coronary artery were compared under free breathing (FB) and deep inspiration breath hold (DIBH) technical modes. Results: The heart volume of the DIBH group was smaller than that of the FB group, and the left and right lung volumes were significantly larger than those of the FB group. In the DIBH group, the heart dose parameters V5, proper lung dose parameters, and left anterior descending coronary artery dose parameters were found lower than that of the FB group, and the differences were statistically significant (P < 0.05). Conclusion: Compared with FB, the DIBH technique can reduce the heart’s size and increase the lung volume when used for radiotherapy after breast-conserving surgery for left breast cancer. It also reduces the dose to the heart, right lung, and left anterior descending coronary artery, thus protecting the heart and lungs.
6
Yang, Yang, Weihai Zhuo, Yiyang Zhao, Tianwu Xie, Chuyan Wang, and Haikuan Liu. "Estimating Specific Patient Organ Dose for Chest CT Examinations with Monte Carlo Method." Applied Sciences 11, no. 19 (September 26, 2021): 8961. http://dx.doi.org/10.3390/app11198961.
Анотація:
Purpose: The purpose of this study was to preliminarily estimate patient-specific organ doses in chest CT examinations for Chinese adults, and to investigate the effect of patient size on organ doses. Methods: By considering the body-size and body-build effects on the organ doses and taking the mid-chest water equivalent diameter (WED) as a body-size indicator, the chest scan images of 18 Chinese adults were acquired on a multi-detector CT to generate the regional voxel models. For each patient, the lungs, heart, and breasts (glandular breast tissues for both breasts) were segmented, and other organs were semi-automated segmented based on their HU values. The CT scanner and patient models simulated by MCNPX 2.4.0 software (Los Alamos National LaboratoryLos Alamos, USA) were used to calculate lung, breast, and heart doses. CTDIvol values were used to normalize simulated organ doses, and the exponential estimation model between the normalized organ dose and WED was investigated. Results: Among the 18 patients in this study, the simulated doses of lung, heart, and breast were 18.15 ± 2.69 mGy, 18.68 ± 2.87 mGy, and 16.11 ± 3.08 mGy, respectively. Larger patients received higher organ doses than smaller ones due to the higher tube current used. The ratios of lung, heart, and breast doses to the CTDIvol were 1.48 ± 0.22, 1.54 ± 0.20, and 1.41 ± 0.13, respectively. The normalized organ doses of all the three organs decreased with the increase in WED, and the normalized doses decreased more obviously in the lung and the heart than that in the breasts. Conclusions: The output of CT scanner under ATCM is positively related to the attenuation of patients, larger-size patients receive higher organ doses. The organ dose normalized by CTDIvol was negatively correlated with patient size. The organ doses could be estimated by using the indicated CTDIvol combined with the estimated WED.
7
Al-Maghrabi, Jaudah A., Elshami M. Elamin, and Hossam A. Abdel-Rahman. "Breast and Axillary Lymph Node Metastases from Advanced Non-small Cell Lung Carcinoma." Journal of King Abdulaziz University - Medical Sciences 18, no. 3 (July 1, 2012): 97–105. http://dx.doi.org/10.4197/med.18-3.7.
Анотація:
Lung cancer metastasizing to the breast is rare. Only few published case reports can be found in the literature. Metastatic lung cancer to the breast and its ipsilateral axillary lymph node is extremely unusual. No awareness of any prior case reports of lung cancer with such a presentation is known. Herein, this study reports an unusual case of a middle aged Saudi female with non-small cell lung cancer that has metastasized, not only to the lungs and the breast, but also to the ipsilateral axillary lymph nodes. It is important for the oncologists to be mindful of rare presentations for such a common malignancy as lung cancer.
8
Markovic, Marina, Dalibor Jovanovic, Zeljko Todorovic, Marija Zivkovic, Aleksandar Dagovic, Slobodanka Mitrović, Marina Petrović, and Jelena Nešić. "Primary Small Cell Carcinoma Of Lung With Metachronous Breast Metastasis." Serbian Journal of Experimental and Clinical Research 18, no. 3 (October 26, 2017): 263–67. http://dx.doi.org/10.1515/sjecr-2016-0087.
Анотація:
Abstract Breast metastases from an extra-mammary malignancy are rare. Among the lung malignancies that metastasise in the breasts, previous literature has described approximately 30 cases of NSCLC and only a few cases of SCLC. Here, we present a 54-year-old woman with metachronous breast metastasis from pulmonary small cell carcinoma. She presented with a soft tissue mass in the right lung hilum. After bronchoscopy with biopsy, SCLC was verified. Th e patient was given 4 cycles of etoposide and cisplatin followed by radiation therapy. Seven months after the diagnosis of primary lung cancer, the patient palpated a mass in her right breast. Clinical examination and further diagnostics revealed the suspected malignancy, and a radical mastectomy was performed. Immunohistochemical findings suggested metastatic SCLC in the breast. Differentiation between primary and metastatic cancer in the breast is very important for therapeutic planning
9
Khan, Sami U., Ying Xia, David Goodale, Gabriella Schoettle, and Alison L. Allan. "Lung-Derived Selectins Enhance Metastatic Behavior of Triple Negative Breast Cancer Cells." Biomedicines 9, no. 11 (October 30, 2021): 1580. http://dx.doi.org/10.3390/biomedicines9111580.
Анотація:
The lung is one of the deadliest sites of breast cancer metastasis, particularly for triple negative breast cancer (TNBC). We have previously shown that the lung produces several soluble factors that may enhance the metastatic behavior of TNBC, including E-, L-, and P-selectin. In this paper, we hypothesize that lung-derived selectins promote TNBC metastatic behavior and may serve as a potential therapeutic target. Lungs were isolated from mice and used to generate lung-conditioned media (CM). Lung-derived selectins were immunodepleted and TNBC migration and proliferation were assessed in response to native or selectin-depleted lung-CM. A 3D ex vivo pulmonary metastasis assay (PuMA) was used to assess the metastatic progression of TNBC in the lungs of wild-type versus triple-selectin (ELP-/-) knockout mice. We observed that individual lung-derived selectins enhance in vitro migration (p ≤ 0.05), but not the proliferation of TNBC cells, and that ex vivo metastatic progression is reduced in the lungs of ELP-/- mice compared to wild-type mice (p ≤ 0.05). Treatment with the pan-selectin inhibitor bimosiamose reduced in vitro lung-specific TNBC migration and proliferation (p ≤ 0.05). Taken together, these results suggest that lung-derived selectins may present a potential therapeutic target against TNBC metastasis. Future studies are aimed at elucidating the pro-metastatic mechanisms of lung-derived selectins and developing a lung-directed therapeutic approach.
10
Wang, Jing, Ramon Ocadiz-Ruiz, Matthew Hall, Grace Bushnell, Sophia Orbach, Joseph Decker, Ravi Raghani, et al. "Abstract LB347: A lung-mimicking synthetic metastatic niche reveals N1 neutrophils drive breast cancer metastatic dormancy in the lungs." Cancer Research 83, no. 8_Supplement (April 14, 2023): LB347. http://dx.doi.org/10.1158/1538-7445.am2023-lb347.
Анотація:
Abstract 3D scaffolds mimicking the environment in the primary tumor or metastatic organs can deconstruct complex niche signals and facilitate the study of cancer progression and metastasis. Here, we reported that a subcutaneous 3D scaffold implant acted as a lung-mimicking dormant metastatic niche in mouse models of metastatic breast cancer, recruiting lung-tropic circulating tumor cells yet suppressing their growth through potent in situ antitumor immunity. We compared it with the immunosuppressive lungs developing lethal metastases and the dormant lungs suppressing tumor growth derived from breast cancer models with varying tumor aggressiveness and host immunity. Our data suggested that breast cancer-induced Gr1+CD11b+Ly6G+ granulocytic myeloid cells (neutrophils) infiltrated the scaffold implants and lungs, secreting the same signal to facilitate the metastatic seeding of lung-tropic cancer cells in these two types of niches. However, circulating neutrophils with opposing phenotypes and functions (N1 and N2) were selectively recruited and enriched in the dormant scaffolds/lungs and immunosuppressive lungs, respectively, responding to two distinct groups of chemoattractants. N1 or N2 neutrophils established activated or suppressive immune environments in the metastatic niches, directing different fates of cancer cells. The clinical relevance of these scientific findings was validated by the strong positive correlation of a high N1-to-N2 neutrophil chemoattractant ratio with a low-grade primary tumor, a low metastases incidence, and a better prognosis in breast cancer patients. Overall, our study revealed the multifaceted roles of neutrophils in regulating lung metastasis and underscored the importance of N1 neutrophils in driving breast cancer metastatic dormancy in the lungs, inspiring next-generation immunotherapy. Citation Format: Jing Wang, Ramon Ocadiz-Ruiz, Matthew Hall, Grace Bushnell, Sophia Orbach, Joseph Decker, Ravi Raghani, Yining Zhang, Aaron Morris, Jacqueline Jeruss, Lonnie Shea. A lung-mimicking synthetic metastatic niche reveals N1 neutrophils drive breast cancer metastatic dormancy in the lungs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB347.
11
Ouakil, N., S. Kechnaoui, G. S. Moussounda Mpika, M. Ijim, O. Fikri, and L. Amro. "Multiple Primary Cancers: Association of Breast Cancer and Lung Carcinoma." Scholars Journal of Medical Case Reports 12, no. 01 (January 20, 2024): 97–99. http://dx.doi.org/10.36347/sjmcr.2024.v12i01.024.
Анотація:
Multiple primary cancers are relatively rare. The association between lung and breast cancer remains exceptional and requires genetic investigation and identification of factors that promote cancer development. We report the case of a 39-year-old patient who was hospitalized for a left lung lesion with nodules in both breasts. Bronchial biopsies confirmed a primary lung adenocarcinoma. A biopsy of the breast revealed an infiltrating carcinoma of NOS type. The treatment consisted of palliative chemotherapy. Although the association of multiple cancers remains rare, their discovery requires a specific therapeutic approach depending on the staging of each cancer.
12
Yamamoto, Shinya, Shigeru Yamagishi, Toshiro Kohno, Ryosuke Tajiri, Toshikazu Gondo, Noboru Yoshimoto, and Nobuko Kusano. "Effective Treatment of a Malignant Breast Phyllodes Tumor with Doxorubicin-Ifosfamide Therapy." Case Reports in Oncological Medicine 2019 (June 18, 2019): 1–5. http://dx.doi.org/10.1155/2019/2759650.
Анотація:
Malignant phyllodes tumors of the breast occur infrequently and are difficult to treat with chemotherapy. Here, we present an effective chemotherapy strategy for recurrent malignant breast phyllodes tumors. A 48-year-old woman was diagnosed with a malignant phyllodes tumor in her right breast and underwent total right mastectomy. One year later, the tumor recurred in the right (a 2.2 cm mass) and left (a 10 cm mass) lungs; pleural effusion was also observed in the left lung. Eight courses of doxorubicin-ifosfamide (AI) therapy were administered. After treatment, the right lung mass and pleural effusion regressed completely and the left lung mass regressed to 2 cm. In conclusion, AI therapy is useful for treating recurrent malignant breast phyllodes tumors.
13
Hozhabri, Hossein, Roxana Sadat Ghasemi Dehkohneh, Seyed Morteza Razavi, S. Mostafa Razavi, Fatemeh Salarian, Azade Rasouli, Jalil Azami, et al. "Comparative analysis of protein-protein interaction networks in metastatic breast cancer." PLOS ONE 17, no. 1 (January 19, 2022): e0260584. http://dx.doi.org/10.1371/journal.pone.0260584.
Анотація:
Metastatic lesions leading causes of the majority of deaths in patients with the breast cancer. The present study aimed to provide a comprehensive analysis of the differentially expressed genes (DEGs) in the brain (MDA-MB-231 BrM2) and lung (MDA-MB-231 LM2) metastatic cell lines obtained from breast cancer patients compared with those who have primary breast cancer. We identified 981 and 662 DEGs for brain and lung metastasis, respectively. Protein-protein interaction (PPI) analysis revealed seven shared (PLCB1, FPR1, FPR2, CX3CL1, GABBR2, GPR37, and CXCR4) hub genes between brain and lung metastasis in breast cancer. Moreover, GNG2 and CXCL8, C3, and PTPN6 in the brain and SAA1 and CCR5 in lung metastasis were found as unique hub genes. Besides, five co-regulation of clusters via seven important co-expression genes (COL1A2, LUM, SPARC, THBS2, IL1B, CXCL8, THY1) were identified in the brain PPI network. Clusters screening followed by biological process (BP) function and pathway enrichment analysis for both metastatic cell lines showed that complement receptor signalling, acetylcholine receptor signalling, and gastric acid secretion pathways were common between these metastases, whereas other pathways were site-specific. According to our findings, there are a set of genes and functional pathways that mark and mediate breast cancer metastasis to the brain and lungs, which may enable us understand the molecular basis of breast cancer development in a deeper levele to the brain and lungs, which may help us gain a more complete understanding of the molecular underpinnings of breast cancer development.
14
Chen, Chiu-Ping, Tung-Ho Chen, Jeng-Fong Chiou, Yi-Ju Chen, Chia-Chun Kuo, Kuo-Hsiung Tseng, Meng-Yun Chung, et al. "Retrospective Analysis for Dose Reduction to Organs at Risk with New Personalized Breast Holder (PERSBRA) in Left Breast IMRT." Journal of Personalized Medicine 12, no. 9 (August 25, 2022): 1368. http://dx.doi.org/10.3390/jpm12091368.
Анотація:
This study evaluated dose differences in normal organs at risk, such as the lungs, heart, left anterior descending artery (LAD), right coronary artery, left ventricle, and right breast under personalized breast holder (PERSBRA), when using intensity-modulated radiation therapy (IMRT). This study evaluated the radiation protection offered by PERSBRA in left breast cancer radiation therapy. Here, we retrospectively collected data from 24 patients with left breast cancer who underwent breast-conserving surgery as well as IMRT radiotherapy. We compared the dose differences in target coverage and organs at risk with and without PERSBRA. For target coverage, tumor prescribed dose 95% coverage, conformity index, and homogeneity index were evaluated. For organs at risk, we compared the mean heart dose, mean left ventricle dose, LAD maximum and mean dose, mean left lung receiving 20 Gy, 10 Gy, and 5 Gy of left lung volume, maximum and mean coronary artery of the right, maximum of right breast, and mean dose. Good target coverage was achieved with and without PERSBRA. When PERSBRA was used with IMRT, the mean dose of the heart decreased by 42%, the maximum dose of LAD decreased by 26.4%, and the mean dose of LAD decreased by 47.0%. The mean dose of the left ventricle decreased by 54.1%, the volume (V20) of the left lung that received 20 Gy decreased by 22.8%, the volume (V10) of the left lung that received 10 Gy decreased by 19.8%, the volume (V5) of the left lung that received 5 Gy decreased by 15.7%, and the mean dose of the left lung decreased by 23.3%. Using PERSBRA with IMRT greatly decreases the dose to organs at risk (left lung, heart, left ventricle, and LAD). This study found that PERSBRA with IMRT can achieve results similar to deep inspiration breath-hold radiotherapy (DIBH) in terms of reducing the heart radiation dose and the risk of developing heart disease in patients with left breast cancer who cannot undergo DIBH.
15
Chaudhari, NilimaMahendrabhai, and Shaila Shah. "Hematological Manifestation in Lung, Breast and Git Malignencies :A Discriptive Study." Annals of Pathology and Laboratory Medicine 5, no. 5 (May 29, 2018): A384–388. http://dx.doi.org/10.21276/apalm.1750.
16
Xin, Xin, Jie Li, Yanqun Zhao, Pei Wang, Bin Tang, Xinghong Yao, Xiongfei Liao, Jiabao Ma, and Lucia Clara Orlandini. "Retrospective Study on Left-Sided Breast Radiotherapy: Dosimetric Results and Correlation with Physical Factors for Free Breathing and Breath Hold Irradiation Techniques." Technology in Cancer Research & Treatment 20 (January 2021): 153303382110624. http://dx.doi.org/10.1177/15330338211062429.
Анотація:
Objectives: In breast radiotherapy, the proximity of the target to sensitive structures together with the uncertainty introduced by respiratory movement, make this treatment one of the most studied to increase its effectiveness. Dosimetric and physical variables play an important role and the study of their correlation and impact on treatment is fundamental. This retrospective study aims to highlight the dosimetric differences of 2 different clinical data sets of patients receiving left-sided breast irradiation in free breathing (FB) or breath hold (BH). Methods: A total of 155 left breast carcinoma patients receiving whole-breast irradiation in FB (73 patients) and BH (82 patients) were enrolled in this study. The dosimetric parameters of the target, heart, left and right lung and right breast were evaluated and compared, and possible correlations were studied in both groups. Results: No significant difference ( P > .05) was found in the target dosimetry; a clear advantage in BH for both high and low doses received by the heart, with reductions of the dosimetric parameters between 27.1% and 100% ( P < .003); for the left lung reductions decreased with increasing dose (−22.4% and −13.4% for doses of 5 and 20 Gy, respectively, P < .003). Conclusion: Significant correlations for BH treatments were registered between the volumes of the target and left lung, and the dosimetric parameters of the heart and left lung. BH treatment brings significant dosimetric advantages to organs at risk for a wide range of patients with different anatomy, target volumes and lung capacity, with additional benefits for small-sized breasts and important lung capacity.
17
Liaw, YS, SH Kuo, PC Yang, CL Chen, and KT Luh. "Nodular amyloidosis of the lung and the breast mimicking breast carcinoma with pulmonary metastasis." European Respiratory Journal 8, no. 5 (May 1, 1995): 871–73. http://dx.doi.org/10.1183/09031936.95.08050871.
Анотація:
Nodular amyloidosis of the breast and lung is a rare condition of unknown aetiology. The disease runs a benign course, but offers a diagnostic problem due to nonspecific histological features. We describe the case of a 56 year old woman with a 5 year history of multiple nodules of both lungs and left breast, clinically mimicking breast carcinoma with pulmonary metastasis. To our knowledge, this is the first case of cytologically proven amyloidosis diagnosed by ultrasound-guided percutaneous transthoracic fine-needle aspiration of pulmonary nodules.
18
Xing, Yue, Shicheng Su, and Erwei Song. "Abstract PO4-25-02: Long-range Deployment of Tumor-antigen Specific Cytotoxic T Lymphocytes Inhibits Lung Metastasis of Breast Cancer." Cancer Research 84, no. 9_Supplement (May 2, 2024): PO4–25–02—PO4–25–02. http://dx.doi.org/10.1158/1538-7445.sabcs23-po4-25-02.
Анотація:
Abstract Effector Immune Cell Deployment (EICD) refers to systemic deployment of anti-tumor effector immune cells in cancer patients, including the priming, circulation, trafficking, activity and fate of the immunocytes, and is a panorama to reflect the generation, distribution and development of anti-tumor immunity. Tumor antigen-specific T cells are the main component of effector immune cells in anti-tumor immune responses, but their systemic deployment in breast cancer patients and the underlying mechanisms remain largely unknown. Here, we identified a cluster of CD8+ T cell exhibiting tissue-resident memory (TRM) phenotype in the tumor-draining lymph nodes (TDLNs) of 487 breast cancer patients, whose abundancy specifically predicts improved lung, but not other target organ metastasis-free survival. Also, high lung CD8+ TRM infiltration is associated with lower metastatic burden in breast cancer patients. Using single-cell RNA sequencing, we observed that in multiple mouse cancer models, CD8+TRM accumulate at early tumor stages when lung metastasis was not identified. Functionally, the CD8+TRM isolated from pre-metastatic lungs of the animals were tumor antigen specific and cytotoxic to the tumor cells. Nevertheless, the abundancy of CD8+TRM in the lungs were dramatically decreased in the lungs upon metastasis establishment. Moreover, in Cd8cre/+ Itgaeloxp/+-diphtheria toxin receptor conditional knockout mice, we unambiguously demonstrated that specific depletion of the CD8+ TRM subset facilitates lung metastasis in vivo, while adoptive transfer of CD8+ TRM successfully inhibited lung metastasis and prolonged survival of the mice. Mechanistically, using cell-tracing techniques in the photo-convertible Kaede-Tg mice, we found that tumor-specific CD8+ TRM were generated in the TDLNs of the mice and were recruited to the lungs via CCL25/CCR9 signaling axis. However, the circulating exosomes secreted by primary tumor cells were taken up by alveolar macrophages and polarized them to release IDO1 and impaired anti-tumor T cell immunity, facilitating lung metastasis. More importantly, inhibition of IDO1 effectively retrieves TRM-mediated protection against lung metastasis. Collectively, we have revealed a cross-talk between tumor cells and the inflammatory environment of distant organs, which could drive lung metastasis by impairing EICD. Our findings also highlight the therapeutic potential of orchestrating EICD in turning “cold” metastatic tumor foci to “hot” ones. Citation Format: Yue Xing, Shicheng Su, Erwei Song. Long-range Deployment of Tumor-antigen Specific Cytotoxic T Lymphocytes Inhibits Lung Metastasis of Breast Cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO4-25-02.
19
Prochazka, Michaela, Per Hall, Giovanna Gagliardi, Fredrik Granath, Bo N. Nilsson, Peter G. Shields, Meredith Tennis, and Kamila Czene. "Ionizing Radiation and Tobacco Use Increases the Risk of a Subsequent Lung Carcinoma in Women With Breast Cancer: Case-Only Design." Journal of Clinical Oncology 23, no. 30 (October 20, 2005): 7467–74. http://dx.doi.org/10.1200/jco.2005.01.7335.
Анотація:
Purpose To analyze the risk of lung cancer in women treated with radiotherapy for breast cancer. We accessed the lung dose in relation to different radiotherapy techniques, provided the excess relative risk (ERR) estimate for radiation-associated lung cancer, and evaluated the influence of tobacco use. Patients and Methods The Swedish Cancer Registry was used to identify 182 women diagnosed with breast and subsequent lung cancers in Stockholm County during 1958 to 2000. Radiotherapy was administered to 116 patients. Radiation dose was estimated from the original treatment charts, and information on smoking history was searched for in case records and among relatives. The risk of lung cancer was assessed in a case-only approach, where each woman contributed a pair of lungs. Results The average mean lung dose to the ipsilateral lung was 17.2 Gy (range, 7.1 to 32.0 Gy). A significantly increased relative risk (RR) of a subsequent ipsilateral lung cancer was observed at ≥ 10 years of follow-up (RR = 2.04; 95% CI, 1.24 to 3.36). Squamous cell carcinoma (RR = 4.00; 95% CI, 1.50 to 10.66) was the histopathologic subgroup most closely related to ionizing radiation. The effect of radiotherapy was restricted to smokers only (RR = 3.08; 95% CI, 1.61 to 5.91). The ERR/Gy for women with latency ≥ 10 years after exposure was 0.11 (95% CI, 0.02 to 0.44). Conclusion Radiotherapy for breast cancer significantly increases the risk of lung carcinoma more than 10 years after exposure in women who smoked at time of breast cancer.
20
Chen, Huiping, Penghan Huang, Jianing Chen, and Erwei Song. "Abstract 6123: High-fat diets promote lung metastasis of breast cancer by activating lung fibroblasts." Cancer Research 82, no. 12_Supplement (June 15, 2022): 6123. http://dx.doi.org/10.1158/1538-7445.am2022-6123.
Анотація:
Abstract Metastasis is the main cause of patient death among many tumor types including breast cancer and breast cancer patients with obesity have higher risk of distant metastases during 10-year follow-up. Diet is one of the main and manageable factors that cause obesity and regular intake of high-fat diets can induce obesity. In addition, fibroblasts, as the most abundant stromal cell type in tumor microenvironment, are involved in cancer metastasis. However, the role of fibroblasts and the downstream mechanism in metastasis of patients with high-fat diet remains unclear. In this study, we fed MMTV-PyMT transgenic mice with high-fat diet to obtain a high-fat tumorigenesis model, and isolate primary lung fibroblasts and then coculture them with breast cancer cells to explore the interaction. We found that a high-fat diet can significantly promote progression of primary breast cancer and lung metastasis, and that before weight difference shows, there is a different chemotactic influence of lung fibroblasts on breast cancer cell between high-fat diet and normal diet group. And we observed increased chemotactic function of primary lung fibroblasts in high-fat diet group. Moreover, tumor cells treated with primary lung fibroblasts in high-fat diet group show increased ability of adhesion, suggesting that high-fat diet chemoattracts breast cancer cell colonization by activating lung fibroblasts. Collectively, we explored the functional differences of lung fibroblast and the key factors for the lung colonization of recruited breast cancer cells. Our findings suggest that dietary patterns are associated with the risk of breast cancer metastasis and targeting activated fibroblasts in pre-metastatic microenvironment may serve as potential early therapeutic strategy to reduce breast cancer lung metastasis. Citation Format: Huiping Chen, Penghan Huang, Jianing Chen, Erwei Song. High-fat diets promote lung metastasis of breast cancer by activating lung fibroblasts [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6123.
21
Roach, Samuel Tanner, Rishi Patel, Serena Thomas, Chinwe Ewenighi-Amankwah, Joseph Dufraine, L. A. Naiche, and Jan Kitajewski. "Abstract 1496: The role of endothelial ACKR1 in breast cancer metastasis." Cancer Research 84, no. 6_Supplement (March 22, 2024): 1496. http://dx.doi.org/10.1158/1538-7445.am2024-1496.
Анотація:
Abstract Background: Tumor cells can co-opt mechanisms of leukocyte extravasation. Atypical Chemokine Receptor 1 (ACKR1) expression in endothelial cells has an established role in promoting leukocyte extravasation; however, the potential for endothelial ACKR1 to facilitate the metastatic process through the extravasation of tumor cells has not been studied. Methods: To understand ACKR1 function, we investigated endothelial ACKR1 expression at the distant metastatic site of the lung, a common site of breast cancer metastasis. We analyzed lung endothelial ACKR1 expression using immunofluorescent staining of lung vasculature during tumor progression in immunocompetent mice bearing orthotopically implanted E0771.LMB breast tumor cells. We assessed the timing of metastatic tumor cell arrival in the lung and evaluated the spatial relationship between disseminated tumor cells and ACKR1-positive vessels. To investigate secreted tumor factors that may mediate ACKR1 regulation in the lung, we performed intratracheal injections of TNF-alpha. We developed an endothelial cell specific ACKR1 conditional knockout mouse model (ACKR1 ECKO) to understand the impact of endothelial ACKR1 on primary tumor growth and subsequent lung metastasis in breast cancer. Results: Our results reveal a significant upregulation of ACKR1 in the lung endothelium of mice implanted with breast cancer cells in the mammary fat pad. Tumor-dependent ACKR1 expression was specifically localized to pulmonary venule endothelium, a common site of leukocyte and tumor cell extravasation. Lung endothelial ACKR1 expression became evident by day 13 after implantation, persisting through endpoint at day 28. Notably, ACKR1 upregulation occurred prior to tumor cell arrival in lungs of tumor bearing mice. We observed spatial clustering of disseminated tumor cells in proximity to ACKR1-positive vessels, implying a preferential site of tumor cell extravasation. In the absence of primary tumors, intratracheal delivery of TNF-alpha induced ACKR1 expression within lungs. When tumors were orthotopically implanted into our ACKR1 ECKO mouse model, we observed a marked decrease in lung metastases compared to control mice. Conclusion/Future Directions: We have determined that pulmonary ACKR1 expression is induced by breast tumors, and vessels expressing ACKR1 appear to act as entry points for lung metastasis. Loss of endothelial ACKR1 reduced metastasis, suggesting that endothelial ACKR1 regulates tumor cell extravasation at distant metastatic sites. We will upregulate lung endothelial ACKR1 expression and directly test its requirement for extravasation using an intravenous tumor cell injection metastasis model. Citation Format: Samuel Tanner Roach, Rishi Patel, Serena Thomas, Chinwe Ewenighi-Amankwah, Joseph Dufraine, L A. Naiche, Jan Kitajewski. The role of endothelial ACKR1 in breast cancer metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1496.
22
Filon, A. M., O. P. Kolesnik, and O. V. Voznyi. "STUDY OF THE STRUCTURE OF DENTAL COMPLICATIONS AND THE EFFECTIVENESS OF THEIR PREVENTION IN PATIENTS WITH BREAST CANCER AND LUNG CANCER IN THE ZAPORIZHZHIA REGION." Ukrainian Dental Almanac, no. 2 (June 27, 2022): 70–79. http://dx.doi.org/10.31718/2409-0255.2.2022.13.
Анотація:
The aim of the work is to analyze the data of patients with malignant neoplasms of the breast and lungs, to investigate the structure of dental complications before and after chemotherapy, to determine the effectiveness of dental prophylaxis.
Materials and methods. 60 cancer patients both men and women were examined, who received chemotherapy at the ONCOLIFE Medical Center (Zaporizhzhia). All respondents were divided into groups by cancer: the first group consisted of 30 patients with lung cancer, the second one 30 patients with breast cancer, and the third (control) group contained 30 people who do not suffer from cancer. The research results are processed by modern statistical methods of analysis on a personal computer using the software package Statistica 13.
Results. It was found that before chemotherapy, dental complications had 70% of patients with lung cancer, 66.7% of patients with breast cancer, 70% of people without cancer, ie there was no statistically significant difference between groups (p> 0.05). In all groups, the results of prevention determined improvement, which was statistically significant by the Wilcoxon test. Although the difference between the groups was statistically significant according to the Kraskel-Wallis test (p <0.05) and there was a statistically significant difference between patients with lung cancer and breast cancer according to the Mann-Whitney test, but the indicators in the group with breast cancer and group without cancer (p> 0.05), which indicates the effectiveness of dental prophylaxis.
Conclusions. Cancer patients receiving antitumor chemotherapy are at risk for certain dental complications, such as mucositis, xerostomia, dygeusia. 13.33% of patients with lung cancer and 16.67% of patients with breast cancer in the study had acute mucositis. Patients with poor oral health, poor oral hygiene, caries and its complications, and incorrect orthopedic structures are more likely to experience dental complications during chemotherapy. The OHI-S hygiene index before prophylaxis was 1.75 (1.40; 2.20) in patients with lung cancer; 1.40 (1.30; 1.80) in patients with breast cancer. The GI gingivitis index before prophylaxis was 1.55 (1.10; 1.90) in patients with lung cancer; 1.25 (1.10; 1.60) in patients with breast cancer. The PMA index before prophylaxis was 62.0 (45.0; 77.0) in patients with lung cancer; 53.0 (43.0; 60.0) in patients with breast cancer.
23
O'Hare, Brendan, Jerrold Lerman, Junko Endo, and Ernest Cutz. "Acute Lung Injury after Instillation of Human Breast Milk or Infant Formula into Rabbits' Lungs." Anesthesiology 84, no. 6 (June 1, 1996): 1386–91. http://dx.doi.org/10.1097/00000542-199606000-00015.
Анотація:
Background Recent interest in shortening the fasting interval after ingestion of milk products demonstrated large volumes of breast milk in the stomach 2 h after breastfeeding. Although aspiration is a rare event, if it were to occur with human breast milk, it is important to understand the extent of the lung injury that might occur. Therefore, the response to instillation of acidified breast milk and infant formula in the lungs of adult rabbits was studied. Methods In 18 anesthetized adult rabbits, 1 of 3 fluids (in a volume of 0.8 ml.kg-1 and pH level of 1.8, acidified with hydrochloric acid); saline, breast milk, or infant formula (SMA, Wyeth, Windsor, Ontario), was instilled into the lungs via a tracheotomy. The lungs were ventilated for 4 h after instillation. Alveolar-to-arterial oxygen gradient and dynamic compliance were measured before and at hourly intervals after instillation. After 4 h, the rabbits were killed and the lungs were excised. Neutrophil infiltration was quantitated by a pathologist blinded to the instilled fluid. A histologic control group of four rabbits was ventilated under study conditions without any intratracheal fluid instillation. Results Alveolar-to-arterial oxygen gradient increased and dynamic compliance decreased significantly during the 4 h after instillation of both breast milk and infant formula compared with baseline measurements and with saline controls (P < 0.05). The neutrophil counts in the lungs from the saline, breast milk, and formula rabbits were significantly greater than those in the control group. Conclusions Instillation of acidified breast milk or infant formula (in a volume of 0.8 ml.kg-1 and pH level of 1.8) into rabbits' lungs induces acute lung injury of similar intensity that lasts at least 4 h.
24
Chen, Siying, Jin Yang, Yang Liu, Haisheng You, Yalin Dong, and Jun Lyu. "Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases." PeerJ 7 (December 17, 2019): e8298. http://dx.doi.org/10.7717/peerj.8298.
Анотація:
Background Reports on the incidence and prognoses of lung metastases when diagnosing breast cancer patients with different subtypes are limited. Our study investigated the effect of molecular sub-typing stratification on the prognoses of lung metastatic breast caner patients. Methods Patients with breast cancer and lung metastases were identified from Surveillance, Epidemiology and End Results population-based data between 2010 and 2015. Univariate and multivariate Cox regression analyses were performed to identify risk factors and prognoses, overall survival (OS) and breast cancer-specific survival for patients with breast cancer lung metastases. Results We identified 6,516 patients with lung metastatic breast cancer, representing 1.7% of the entire cohort and 30.4% of the subset with metastatic disease. This included 2,940 hormone receptor (HR)+/HER2− patients, 852 HR+/HER2+ patients, 547 HR−/HER2+ patients and 983 triple-negative patients. The median OS for all lung metastatic patients was 13 months. Multivariate analysis revealed that those lung metastatic breast cancer patients of older age (>80), black race, with poorly differentiated tumors, carcinoma histology, triple-negative subtype, more metastatic sites and no surgery, and no chemotherapy showed significantly poor survival, both overall and breast cancer-specific. Conclusions Our findings show that molecular sub-type and more metastatic sites might have significant influence on the incidence and prognosis of breast cancer lung metastases. We also identified several prognostic factors that could guide therapy selection in the treatment of lung metastatic patients.
25
Ferrari, Annamaria, Giovanni Ivaldi, Maria Cristina Leonardi, Elena Rondi, and Roberto Orecchia. "Prone Breast Radiotherapy in a Patient with Early Stage Breast Cancer and a Large Pendulous Breast." Tumori Journal 95, no. 3 (May 2009): 394–97. http://dx.doi.org/10.1177/030089160909500323.
Анотація:
In women with large and pendulous breasts postoperative radiotherapy in the supine position could represent a technical challenge because of the resulting dose inhomogeneity and the large amount of lung and heart receiving a high percentage of the prescribed dose. Breast-conserving surgery is therefore relatively contraindicated in these patients. Alternative positions for radiation therapy treatment have been proposed, and prone breast irradiation in particular has been recognized as a useful alternative to conventional treatment in the supine position. We report the case of a large-breasted patient treated in prone position in our radiation therapy division.
26
Zeng, Fan, Rui-Jun Ju, Lei Liu, Hong-Jun Xie, Li-Min Mu, and Wan-Liang Lu. "Efficacy in Treating Lung Metastasis of Invasive Breast Cancer with Functional Vincristine Plus Dasatinib Liposomes." Pharmacology 101, no. 1-2 (October 7, 2017): 43–53. http://dx.doi.org/10.1159/000480737.
Анотація:
Background: The metastasis of breast cancer is the leading cause of death, while lung metastasis is a major clinical phenomenon in patients with invasive breast cancer. The current treatment option comprising surgery, radiation, and standard chemotherapy cannot achieve a satisfactory effect on the treatment of lung metastasis of breast cancer. In this study, we report the potential of preventing lung metastasis of invasive breast cancer using the newly developed functional vincristine plus dasatinib liposomes. Methods: The investigations were performed on invasive breast cancer MDA-MB-231 cells in vitro and in lung metastatic model of invasive breast cancer MDA-MB-231 cells in nude mice. Results: The functional drug liposomes were able to induce cell cycle arrest at G2/M phase, induce apoptosis, inhibit adhesion, migration, and invasion of breast cancer cells in vitro, and prevent lung metastasis of breast cancer in nude mice. Conclusion: These findings indicate a potential clinical use of functional vincristine plus dasatinib liposomes for treating metastatic breast cancer.
27
Schumacher, Udo, Dhia Mukthar, and Thomas Schenker. "Reactivity of Monoclonal Antibodies Directed against Lung Cancer Antigens with Human Lung, Breast and Colon Cancer Cell Lines." Disease Markers 11, no. 5-6 (1993): 225–37. http://dx.doi.org/10.1155/1993/619781.
Анотація:
A panel of monoclonal antibodies (n=72 including controls) directed against lung cancer antigens was screened immunohistochemically against a panel of seven human lung cancer cell lines (including small cell carcinoma, squamous cell carcinoma, adenocarcinoma and mesothelioma), six human breast cancer cell lines and one human colon cancer cell line, The majority of the antibodies (n=42) reacted also with antigens present on breast and colon cancer cell lines, This cross reactivity especially between lung and breast cancer cell lines is not altogether unexpected since antigens common to breast and lung tissue including their neoplasms such as MUC1 antigen have been described, Our results indicate that epitopes shared by lung and breast cancers are probably more common than previously thought. The relevance for prognosis and therapy of these shared antigens, especially as disease markers in breast cancer, has to be investigated.
28
Williams, Abbey E., and Lisa M. Arendt. "Abstract 1316: Immune cell dysfunction is enhanced in a mouse model of obesity-associated breast cancer lung metastasis." Cancer Research 83, no. 7_Supplement (April 4, 2023): 1316. http://dx.doi.org/10.1158/1538-7445.am2023-1316.
Анотація:
Abstract Obesity is known to worsen the overall prognosis of breast cancer patients. Breast cancer patients with a body mass index (BMI) of ≥30 kg/m2 have an increased risk for metastatic disease compared to patients with a BMI in the normal range. Further studies are necessary to understand the mechanisms driving increased breast cancer metastasis in obese patients, particularly to the lung. Although immune cells like neutrophils and myeloid derived suppressor cells have been studied in breast cancer metastasis of the lung, little is known how adaptive immune cells function in metastatic niche of the lung in obesity. To investigate these gaps, we fed 3-week-old female FVB/N mice either a low-fat diet (LFD) or high-fat diet (HFD) for 16 weeks to induce obesity. We then injected estrogen receptor positive (ER+) TC2 cells into the mammary fat pad. Tumors grew to 0.5 cm in diameter then were surgically removed. Lung tissue was collected 8 weeks after tumor removal to examine progression of metastatic disease, and T cell populations were quantified in metastatic lung tissue from obese and lean mice using flow cytometry. Lungs from obese mice showed a significant increase of total immune cells (CD45) and a decrease in total T cells and natural killer cells (NK) compared with controls. CD3+ cells and CD8+ T cells from obese mice expressed higher levels of programmed cell death protein-1 (PD1), a marker of T cell dysfunction. These results suggest that T cells from the lungs of obese mice may have a greater level of T cell dysfunction than controls. To further investigate how obesity alters the function of T cells, CD45+ cells were sorted from lungs from lean and obese mice with and without metastasis, and gene expression was examined using the Nanostring nCounter Immune Exhaustion panel. Immune cells from the lungs of obese non-tumor-bearing mice showed increased expression of NK exhaustion markers and increased TCR signaling. In metastatic lungs from obese mice, immune cells also showed impaired interferon and tumor necrosis factor signaling and an increase in genes associated with exhaustion in NK cells. Further analysis showed upregulated expression of genes associated with senescence in immune cells from metastatic lungs of obese mice. These data suggest that obesity may increase dysfunctional states of T cells and NK cells, leading to enhanced metastatic growth of breast cancer cells. Citation Format: Abbey E. Williams, Lisa M. Arendt. Immune cell dysfunction is enhanced in a mouse model of obesity-associated breast cancer lung metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1316.
29
Macedo, Joana Espiga de. "Synchronous lung and breast cancer." World Journal of Respirology 7, no. 1 (2017): 29. http://dx.doi.org/10.5320/wjr.v7.i1.29.
30
Sousaris, Nicholas, Geoffrey Mendelsohn, and Richard G. Barr. "Lung Cancer Metastatic to Breast." Ultrasound Quarterly 29, no. 3 (September 2013): 205–9. http://dx.doi.org/10.1097/ruq.0b013e3182a00fc4.
31
Fabian, Claire B., and David J. Dabbs. "Breast Carcinoma versus Lung Adenocarcinoma: The Immunohistochemical Discrimination of Breast Carcinoma Metastatic in Lung." Breast Journal 3, no. 3 (May 1997): 135–41. http://dx.doi.org/10.1111/j.1524-4741.1997.tb00157.x.
32
Takeda, Yuji, Koji Tsuta, Yasuo Shibuki, Tatsuhiro Hoshino, Naobumi Tochigi, Akiko Miyagi Maeshima, Hisao Asamura, Yuko Sasajima, Tsuyoshi Ito, and Yoshihiro Matsuno. "Analysis of Expression Patterns of Breast Cancer–Specific Markers (Mammaglobin and Gross Cystic Disease Fluid Protein 15) in Lung and Pleural Tumors." Archives of Pathology & Laboratory Medicine 132, no. 2 (February 1, 2008): 239–43. http://dx.doi.org/10.5858/2008-132-239-aoepob.
Анотація:
Abstract Context.—The lung is the most common site of metastasis during the natural history of malignant tumors. Breast carcinoma has a propensity for distant metastasis, and the lung and pleura are among the most common metastatic sites. Although it is often difficult to make a clear-cut differential diagnosis between the two, distinguishing primary lung carcinoma from breast carcinoma metastatic to the lung is important because the treatment modalities are different. Objective.—To elucidate the utility of mammaglobin and gross cystic disease fluid protein 15 (GCDFP-15), which are known to be breast-specific antigens, in distinguishing various primary lung and pleural tumors from breast carcinoma metastasizing to the lung. Design.—A total of 20 cases of breast carcinoma metastatic to the lung and 263 tumors of nonbreast origin located in the lung and pleura were analyzed. Results.—Of the 20 cases of breast carcinoma metastatic to the lung, 10 (50.0%) were immunoreactive for mammaglobin and 9 (45.0%) for GCDFP-15, the frequency of positivity being slightly higher for the former than for the latter. The area immunopositive for mammaglobin showed more diffuse staining than the area immunopositive for GCDFP-15. Furthermore, the specificity of mammaglobin for breast carcinoma metastatic to the lung was superior (98.9%) to that of GCDFP-15 (91.8%). Conclusion.—The sensitivity of mammaglobin is equal or superior to that of GCDFP-15 for investigation of breast carcinoma. Immunopositivity for mammaglobin is more diffuse than that for GCDFP-15. In terms of practical diagnosis, mammaglobin immunohistochemistry can serve as a differential marker of breast carcinoma and should be added to the immunohistochemical panel.
33
Dansin, Eric, Aurélien Carnot, Véronique Servent, Dorothée Daussay, Yves-Marie Robin, Ecaterina Surmei-Pintilie, Géraldine Lauridant, Clothilde Descarpentries, Françoise Révillion, and Claire Delattre. "EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report." Case Reports in Oncology 8, no. 1 (March 14, 2015): 164–68. http://dx.doi.org/10.1159/000381014.
Анотація:
Breast metastasis from other primary carcinoma is very rare and could be difficult to identify despite immunohistochemistry analysis. Breast metastasis from lung adenocarcinoma can mimic triple-negative breast cancer. Given the prognosis and therapeutic challenges, a correct diagnosis appears essential, and molecular biomarkers could be useful. We report the case of a 52-year-old woman with a breast mass initially diagnosed as primary breast cancer and secondarily attached to breast metastasis from an EGFR-mutated lung adenocarcinoma. The same activating EGFR mutations were identified in both the primary lung carcinoma and the breast metastasis.
34
Reeves, Mark E., Matthew Firek, Shin-Tai Chen, and Yousef Amaar. "The RASSF1 Gene and the Opposing Effects of the RASSF1A and RASSF1C Isoforms on Cell Proliferation and Apoptosis." Molecular Biology International 2013 (November 12, 2013): 1–9. http://dx.doi.org/10.1155/2013/145096.
Анотація:
RASSF1A has been demonstrated to be a tumor suppressor, while RASSF1C is now emerging as a growth promoting protein in breast and lung cancer cells. To further highlight the dual functionality of the RASSF1 gene, we have compared the effects of RASSF1A and RASSF1C on cell proliferation and apoptosis in the presence of TNF-α. Overexpression of RASSF1C in breast and lung cancer cells reduced the effects of TNF-α on cell proliferation, apoptosis, and MST1/2 phosphorylation, while overexpression of RASSF1A had the opposite effect. We also assessed the expression of RASSF1A and RASSF1C in breast and lung tumor and matched normal tissues. We found that RASSF1A mRNA levels are significantly higher than RASSF1C mRNA levels in all normal breast and lung tissues examined. In addition, RASSF1A expression is significantly downregulated in 92% of breast tumors and in 53% of lung tumors. Conversely, RASSF1C was upregulated in 62% of breast tumors and in 47% of lung tumors. Together, these findings suggest that RASSF1C, unlike RASSF1A, is not a tumor suppressor but instead may play a role in stimulating survival in breast and lung cancer cells.
35
Franceschini, Davide, Tiziana Comito, Anna Di Gallo, Veronica Vernier, Marco A. Marzo, Luciana Di Cristina, Beatrice Marini, et al. "Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial." Current Oncology 29, no. 10 (October 17, 2022): 7858–67. http://dx.doi.org/10.3390/curroncol29100621.
Анотація:
Aims: We report the mature toxicity data of a phase II non-randomized trial on the use of SBRT for lung and liver oligometastases. Methods: Oligometastatic patients from breast cancer were treated with SBRT for up to five lung and/or liver lesions. Inclusion criteria were: age > 18 years, ECOG 0–2, diagnosis of breast cancer, less than five lung/liver lesions (with a maximum diameter <5 cm), metastatic disease confined to the lungs and liver or extrapulmonary or extrahepatic disease stable or responding to systemic therapy. Various dose–fractionation schedules were used. Then, a 4D-CT scan and FDG-CTPET were acquired for simulation and fused for target definition. Results: From 2015 to 2021, 64 patients and a total of 90 lesions were irradiated. Treatment was well tolerated, with no G 3–4 toxicities. No grade ≥3 toxicities were registered and the coprimary endpoint of the study was met. Median follow-up was 19.4 months (range 2.6–73.1). Conclusions: The co-primary endpoint of this phase II trial was met, showing excellent tolerability of SBRT for lung and liver oligometastatic in breast cancer patients. Until efficacy data will mature with longer follow-up, SBRT should be regarded as an opportunity for oligometastatic breast cancer patients.
36
Fosu, Kwadwo, Jude Tetteh Quarshie, Kwabena Amofa Nketia Sarpong, and Anastasia Rosebud Aikins. "Inverse Comorbidity between Down Syndrome and Solid Tumors: Insights from In Silico Analyses of Down Syndrome Critical Region Genes." Genes 14, no. 4 (March 26, 2023): 800. http://dx.doi.org/10.3390/genes14040800.
Анотація:
An inverse comorbidity has been observed between Down syndrome (DS) and solid tumors such as breast and lung cancers, and it is posited that the overexpression of genes within the Down Syndrome Critical Region (DSCR) of human chromosome 21 may account for this phenomenon. By analyzing publicly available DS mouse model transcriptomics data, we aimed to identify DSCR genes that may protect against human breast and lung cancers. Gene expression analyses with GEPIA2 and UALCAN showed that DSCR genes ETS2 and RCAN1 are significantly downregulated in breast and lung cancers, and their expression levels are higher in triple-negative compared to luminal and HER2-positive breast cancers. KM Plotter showed that low levels of ETS2 and RCAN1 are associated with poor survival outcomes in breast and lung cancers. Correlation analyses using OncoDB revealed that both genes are positively correlated in breast and lung cancers, suggesting that they are co-expressed and perhaps have complementary functions. Functional enrichment analyses using LinkedOmics also demonstrated that ETS2 and RCAN1 expression correlates with T-cell receptor signaling, regulation of immunological synapses, TGF-β signaling, EGFR signaling, IFN-γ signaling, TNF signaling, angiogenesis, and the p53 pathway. Altogether, ETS2 and RCAN1 may be essential for the development of breast and lung cancers. Experimental validation of their biological functions may further unravel their roles in DS and breast and lung cancers.
37
Valentín López, José Carlos, Alice Y. Ho, Beverly Moy, Steven J. Isakoff, Dejan Juric, Leif W. Ellisen, Jeffrey M. Peppercorn, Aditya Bardia, Kevin S. Hughes, and Neelima Vidula. "Utilizing Natural Language Processing (NLP) to identify breast cancer associated-lung metastases from pathology reports to delineate characteristics and challenges of this common site of breast cancer recurrence." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): e13592-e13592. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e13592.
Анотація:
e13592 Background: NLP (artificial intelligence) can automate the identification of records in large datasets. The purpose of this study was to evaluate the feasibility of NLP to identify breast cancer-associated lung metastases to understand clinical characteristics and challenges posed by this common site of breast cancer recurrence. Methods: Patients with pathologically confirmed breast cancer associated-lung metastases seen at a large academic center between 3/2012-5/2019 were identified using NLP of institutional pathology reports, with an IRB approved protocol. Chart review was performed to confirm breast cancer associated-lung metastases and determine clinical and pathological features. Results: Using NLP, 32 patients with pathology reports denoting breast cancer associated-lung metastases were identified, with pathologic confirmation of lung biopsy tissue in the majority of cases (24), and pleural fluid specimens (8) on the remainder. Ten of 32 (31%) were HR+/HER2-, 3/32 (9.3%) HER2+, and 19/32 (59%) TNBC. The majority were invasive ductal carcinoma (21/26) with the remainder invasive lobular carcinoma (2/26) or mixed histology (3/26). Median age at lung metastasis diagnosis was 62 years (range 31-88). The median time to development of lung metastasis following primary breast cancer was 5.6 years (range 0-24.8 years). Fifty six percent of lung metastases were detected on imaging and 44% by symptoms including dyspnea, cough, or pain. Tumor tissue genotyping results on the lung metastases were available for 8 patients showing PI3KCA (5), TP53 (3), SMARCA4 (2), ERBB2 (1), FGFR3 (1), ATM (1), CDK4 (1), MYC (1), and ESR1 (1). Treatment after diagnosis of lung metastases included hormone therapy (61%), chemotherapy (84%), lung irradiation (26%), and surgical resection of lung metastases (6%). Lung metastases were associated with considerable morbidity including pleural effusion (15%), dyspnea (6%), pneumothorax (3%), hemothorax (3%), and atelectasis (3%). Patients diagnosed with lung metastases had brain (32%), bone (35%), renal (6%), skin (3%) and adrenal (3%) metastases during disease course. Conclusions: NLP can help identify organ specific metastases from pathology reports, such as breast cancer associated-lung metastases, which can then facilitate observational, translational, and clinical research to characterize and address challenges posed by this common site of breast cancer recurrence. This cohort of patients highlights the morbidity of breast cancer associated-lung metastases and potential role of NLP for disease characterization and clinical research. (Support from ASCO Medical Student Rotation for Underrepresented Populations Award.)
38
Schembri, Ashley, Susan Mercieca, Nick Courtier, and Francis Zarb. "The impact of breast size on mean lung dose for patients receiving tangential radiotherapy to the whole breast." Journal of Radiotherapy in Practice 15, no. 2 (April 4, 2016): 181–88. http://dx.doi.org/10.1017/s1460396916000091.
Анотація:
AbstractPurposeTo explore the impact of breast size on mean lung dose (MLD) for patients receiving breast radiotherapy.MethodologyChest wall separation (CWS), volume of tissue receiving 95% isodose and MLD were measured on 80 radiotherapy treatment plans of patients receiving tangential radiotherapy treatment to the whole breast. Breast size was categorised as small (CWS<25 cm and planned target volume (PTV)<1,500 cm3) and large (CWS>25 cm and PTV>1500 cm3). Pearson’s correlation and independent sample t-test were used to analyse data.ResultsMLD was not affected by CWS (r=−0·13, p=0·24) nor volume of tissue receiving 95% isodose (r=−0·08, p=0·49). Significant variation between small and large breasts was noted for CWS (t=8·24, p=0·00) and volume of tissue receiving 95% isodose (t=5·68, p=0·00). No significant variation was noted between small and large breast for MLD (t=−0·26, p=0·80) and between left and right breasts for CWS (t=1·42, p=0·16) and volume of tissue receiving 95% isodose (t=−1·08, p=0·28). Significant difference between left (18–808 cGy) and right breast (325–365 cGy) was demonstrated for MLD (t=3·03, p=0·00).ConclusionThis study demonstrated lack of correlation between breast size and MLD. Further research is recommended for justification of alternative techniques for this subgroup of patients to provide optimised radiotherapy delivery.
39
Genç, Berhan, Aynur Solak, Neslin Şahin, and Aşkın Gülşen. "Metastasis to the Male Breast from Squamous Cell Lung Carcinoma." Case Reports in Oncological Medicine 2013 (2013): 1–4. http://dx.doi.org/10.1155/2013/593970.
Анотація:
Metastasis to breast from extra mammarian organs is quite rare with an incidence of 0.5–3%. Malignancies that most commonly metastasize to breast are lymphomas, leukemias, and malignant melanoma. Metastasis of lung cancer to breast is a very rare condition. We present here a case with squamous cell lung cancer that metastasized to breast. A 65-year-old man presented with cough in addition to a mass in the left breast, which had been noted 3 weeks ago and grown gradually since then. A histopathological diagnosis of metastasis of squamous lung cancer was made for the mass in the left breast. PET/CT scan showed no distant metastasis. Chemoradiation therapy was applied for lung cancer. As the prognosis of such patients is extremely poor, it is of a great importance to distinguish a primary breast cancer from a metastatic breast lesion in order to determine the appropriate treatment modality.
40
Urooj, Tabinda, Bushra Wasim, Shamim Mushtaq, Syed Nudrat Nawaid Shah, and Muzna Shah. "Cancer Cell-derived Secretory Factors in Breast Cancer-associated Lung Metastasis: Their Mechanism and Future Prospects." Current Cancer Drug Targets 20, no. 3 (March 19, 2020): 168–86. http://dx.doi.org/10.2174/1568009620666191220151856.
Анотація:
: In Breast cancer, Lung is the second most common site of metastasis after the bone. Various factors are responsible for Lung metastasis occurring secondary to Breast cancer. Cancer cellderived secretory factors are commonly known as ‘Cancer Secretomes’. They exhibit a prompt role in the mechanism of Breast cancer lung metastasis. They are also major constituents of hostassociated tumor microenvironment. Through cross-talk between cancer cells and the extracellular matrix components, cancer cell-derived extracellular matrix components (CCECs) such as hyaluronan, collagens, laminin and fibronectin cause ECM remodeling at the primary site (breast) of cancer. However, at the secondary site (lung), tenascin C, periostin and lysyl oxidase, along with pro-metastatic molecules Coco and GALNT14, contribute to the formation of pre-metastatic niche (PMN) by promoting ECM remodeling and lung metastatic cells colonization. Cancer cell-derived secretory factors by inducing cancer cell proliferation at the primary site, their invasion through the tissues and vessels and early colonization of metastatic cells in the PMN, potentiate the mechanism of Lung metastasis in Breast cancer. : On the basis of biochemical structure, these secretory factors are broadly classified into proteins and non-proteins. This is the first review that has highlighted the role of cancer cell-derived secretory factors in Breast cancer Lung metastasis (BCLM). It also enumerates various researches that have been conducted to date in breast cancer cell lines and animal models that depict the prompt role of various types of cancer cell-derived secretory factors involved in the process of Breast cancer lung metastasis. In the future, by therapeutically targeting these cancer driven molecules, this specific type of organ-tropic metastasis in breast cancer can be successfully treated.
41
Oura, Shoji, Mitsuo Mori, and Shinichiro Makimoto. "A Case of Solitary Lung Metastasis of Breast Cancer Successfully Treated with Stereotactic Body Radiotherapy after Chemotherapy." Case Reports in Oncology 13, no. 1 (April 9, 2020): 398–402. http://dx.doi.org/10.1159/000506733.
Анотація:
A 62-year-old woman with triple-negative breast cancer underwent breast-conserving surgery followed by adjuvant chemotherapy and radiotherapy to the breast. The patient developed a solitary lung metastasis at the left hilum 44 months after the operation. The lung metastasis responded partially to capecitabine chemotherapy, but showed regrowth in 7 months. The patient received second-line oral cyclophosphamide (CPA) chemotherapy, resulting in marked tumor regression without new lesions for 10 months. To further control the lung metastasis, stereotactic body radiotherapy (SBRT; 5.1 Gy ×10 fractions) under breath holding without a localization device was given to the regressed lung metastasis after CPA therapy. Positron emission tomography at 24 months after the completion of SBRT did not show any recurrences, and the patient has been well for 100 months without any recurrences. Breast oncologist should take SBRT into consideration to treat lung oligometastasis of breast cancer especially locating at the lung hilum with curative intent.
42
Prat, Aleix, Barbara Adamo, Cheng Fan, Maria Vidal, Patricia Galvan, Enriqueta Felip, Jose Maria Del Campo, Josep Tabernero, and Javier Cortes. "Molecular identification of basal-like breast cancer through genomic analyses across five cancer types." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 1011. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.1011.
Анотація:
1011 Background: Common molecular alterations in different types of cancer are being identified and these might be successfully targeted regardless of the tumor´s tissue of origin. To better understand the genomic relationships among different types of cancer, we explored global gene expression patterns across breast, lung, ovarian, brain and colorectal cancers. Methods: A unified set of 1,707 samples of 5 human cancer types (breast [n=547], lung [squamous and adenocarcinomas, n=249], ovarian [serous carcinoma, n=489], brain [glioblastoma multiforme, n=202] and colorectal [n=220]) from The Cancer Genome Atlas (TCGA) project was evaluated. All microarrays were performed at the University of North Carolina under the same protocol and platform. All samples provided in each publication of TCGA were used, except for lung adenocarcinomas where we used TCGA public data. Consensus clustering was used to identify molecular entities, and breast cancer intrinsic subtyping was performed using the PAM50 predictor. Results: A total of 6 distinct and robust molecular entities were identified representing tumors from breast luminal/HER2-enriched, breast Basal-like, lung, ovarian, brain and colorectal cancers. Strikingly, 55%, 26%, 16% of Basal-like breast cancers were found to be more similar to squamous cell lung carcinomas, lung adenocarcinomas and ovarian cancers, respectively, compared to breast luminal/HER2-enriched tumors. Breast cancer intrinsic subtyping identified a Basal-like profile in 55% of squamous cell lung cancers, 53% of ovarian cancers and 8% of lung adenocarcinomas. Finally, single genes and gene signatures tracking cancer-related biological processes such as proliferation, angiogenesis and immune activation were found highly expressed in different proportions across the 6 molecular entities. Conclusions: These data suggest that breast tumors of the Basal-like subtype have a distinct cell of origin compared to luminal/HER2-enriched tumors. Clinical trials focusing on tumors with common profiles and/or biomarker expression rather than their tissue of origin are warranted with a special focus on Basal-like breast cancer, squamous cell lung carcinoma and serous ovarian cancer.
43
Saad Abdalla Al-Zawi, Abdalla, Andrzej Ratajczak, Philip Idaewor, Mohamed Elamass, Anita Lazarevska, Elizabeth Tan, Marina Barron, and Amira Asaad. "Primary lung cancer with metastasis to the ipsilateral breast-a case report." International Journal of Research in Medical Sciences 6, no. 1 (December 23, 2017): 334. http://dx.doi.org/10.18203/2320-6012.ijrms20175744.
Анотація:
The metastasis of extra-mammary malignancy to breast is extremely rare; literature reports the incidence between 0.4-1.3%. Primary sites include the contralateral breast, leukaemia, lymphoma, malignant melanoma, sarcoma, lung, prostate, ovary, colon and the stomach. Here we present a rare case in which lung cancer was found to metastasise to the breast. Initially the patient presented with chest symptoms and a left breast lump was detected clinically. The radiological and histological investigations confirmed the diagnosis of primary lung cancer with breast metastases. Prognosis of such cases is generally poor.
44
Freitas, Nilceana, Priscila Watanabe, Jean Paiva, Carolina Bezerril, Marcelo Valentim, Thais Gontijo, Flavia Araujo, and Ruffo Freitas-Junior. "Abstract PO5-22-03: Influence of the surgical clip concerning the dose and volume of irradiated surrounding tissues including lung and heart in the planning of radiotherapy boost with conservative breast surgery with and without oncoplasty." Cancer Research 84, no. 9_Supplement (May 2, 2024): PO5–22–03—PO5–22–03. http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-22-03.
Анотація:
Abstract Introduction: Patients with the highest risk of breast cancer undergoing conservative surgery receive an additional boost dose of radiotherapy in the tumor bed during treatment planning, which is known to bring benefits in local control. Objectives: To evaluate the influence of the surgical clip concerning the volume of surrounding tissues irradiated during radiotherapy, in patients submitted to conservative breast surgery with and without oncoplasty. Materials/Methods. The analyzed variables were defined as: the volume of the boost (V100 Boost) and breast tissue (V100 Breast) that received 100% of the prescribed dose during the radiotherapy planning and the volume of the heart (V40 Heart) and lung (V40 Lung) that received 40% of the prescribed dose during the boost phase in patients undergoing treatment with breast conservation. The variables were compared about the insertion or not of the surgical clip and the influence of oncoplastic surgery on the volume of irradiated tissues of the breast, boost, heart and lung during radiotherapy planning. Student's t-test (95%CI; p< 0.05) was used to compare mean volumes as a function of the presence or not of surgical clips and oncoplastic surgery. Results: Retrospective study included 183 women with breast cancer who underwent treatment with conservative breast surgery and radiotherapy of the whole breast, followed by sequential boost, between January 2011 and January 2021. Boost, breast, heart, and lung volumes were evaluated during planning for conformational radiotherapy. The results showed a significant difference between the average boost volumes when the patient was clipped. The average boost volume that received 100% of the prescribed dose was V100 Boost=244.22cm³ (SD±158) in the absence of the clip. In the presence of 1 or 2 clips, this average was V100 Boost= 94.87cm³ (SD±37) and with 3 or more clips it was V100 Boost= 96.99cm³ (SD±39) (p< 0.001). There was also a significant difference in mean breast volumes that received 100% of the prescribed dose. In the absence of the clip, the V100 Breast=373.16 cm³ (SD±222) and when 1 or 2 clips were present, the V100 Breast=235.28 cm³ (SD±125) (p=0.01). The analyzes of the mean volumes of the heart (V40 Heart) and lung (V40 Lung) that received 40% of the prescribed boost dose were not statistically significant, regardless of the presence and number of clips. For the oncoplasty group, there was no statistical difference between the means of boost, breast, heart and lung volumes. Conclusion: The presence of the surgical clip reduced the volume of the boost and the breast that received 100% of the dose in the radiotherapy planning. The volume of the boost (V100 Boost), which received 100% of the dose prescribed during radiotherapy planning, was smaller in patients with a surgical clip, as was the volume of irradiated breast tissue (V100 Breast) in clipped patients. The volume of irradiated tissue in the heart (V40 Heart) and lung (V40 Lung) that received 40% of the prescribed dose during the boost phase in radiotherapy planning did not suffer statistical differences in insertion or not of the surgical clip. Oncoplastic surgery and the presence of surgical clips did not influence the volumes of irradiated boost, breast, heart and lung tissues during the radiotherapy planning of patients undergoing conservative surgical treatment of the breast. Table: Means of boost, breast, heart and lung irradiated volumes according to the presence or absence of clips and oncoplastic surgery Table. Means of boost, breast, heart and lung irradiated volumes according to the presence or absence of clips and oncoplasty surgery Variable (cm3) Clip p valor Oncoplasty p valor With Without With Without Means Means Means Means V100% Boost 94 244 < 0,001 102 118 0,906 V100% Breast 235 373 0,01 271 272 0,816 V40% Heart 1,10 4,52 0,33 1,96 1,39 0,903 V40% Lung 56,66 56,10 0,93 51,63 52,53 0,796 Citation Format: Nilceana Freitas, Priscila Watanabe, Jean Paiva, Carolina Bezerril, Marcelo Valentim, Thais Gontijo, Flavia Araujo, Ruffo Freitas-Junior. Influence of the surgical clip concerning the dose and volume of irradiated surrounding tissues including lung and heart in the planning of radiotherapy boost with conservative breast surgery with and without oncoplasty [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-22-03.
45
Kempisty, Anna, Ewa Augustynowicz-Kopec, Lucyna Opoka, and Monika Szturmowicz. "Mycobacterium szulgai Lung Disease or Breast Cancer Relapse—Case Report." Antibiotics 9, no. 8 (August 5, 2020): 482. http://dx.doi.org/10.3390/antibiotics9080482.
Анотація:
Cancers are one of the risk factors of non-tuberculous mycobacterial (NTM) lung disease. The majority of data in this group of patients concern infections caused by Mycobacterium avium—the most prevalent NTM species worldwide. In contrast, limited information can be found regarding the uncommon NTM such as Mycobacterium szulgai. We present the case of M. szulgai lung disease in a patient with a history of breast cancer. Coexistence of NTM lung disease and breast cancer lung metastasis as well as primary lung cancer was suspected. Finally, neoplastic disease was ruled out based on negative results of endobronchial biopsy and negative tumor markers for lung and breast cancer. M. szulgai lung disease was successfully treated with rifampicin, ethambutol and clarithromycin.
46
Patel, Urvi, David Susman, and Alison L. Allan. "Influence of Extracellular Vesicles on Lung Stromal Cells during Breast Cancer Metastasis." International Journal of Molecular Sciences 24, no. 14 (July 22, 2023): 11801. http://dx.doi.org/10.3390/ijms241411801.
Анотація:
Breast cancer is a prominent cause of cancer diagnosis and death in women globally, with over 90% of deaths being attributed to complications that arise from metastasis. One of the common locations for breast cancer metastasis is the lung, which is associated with significant morbidity and mortality. Curative treatments for metastatic breast cancer patients are not available and the molecular mechanisms that underlie lung metastasis are not fully understood. In order to better treat these patients, identifying events that occur both prior to and during metastatic spread to the lung is essential. Several studies have demonstrated that breast cancer-derived extracellular vesicles secreted from the primary breast tumor play a key role in establishing the lung pre-metastatic niche to support colonization of metastatic tumor cells. In this review, we summarize recent work supporting the influence of extracellular vesicles on stromal components of the lung to construct the pre-metastatic niche and support metastasis. Furthermore, we discuss the potential clinical applications of utilizing extracellular vesicles for diagnosis and treatment. Together, this review highlights the dynamic nature of extracellular vesicles, their roles in breast cancer metastasis to the lung, and their value as potential biomarkers and therapeutics for cancer prevention.
47
Chia, Shi Biao, Bryan Johnson, Julio A. Aguirre-Ghiso, Mercedes Rincon, and James DeGregori. "Abstract 5131: Pulmonary influenza infection promotes the awakening of dormant metastatic breast cancer cells." Cancer Research 83, no. 7_Supplement (April 4, 2023): 5131. http://dx.doi.org/10.1158/1538-7445.am2023-5131.
Анотація:
Abstract Breast cancer is the most common form of cancer and the second cancer-causing death in females. Although remission rates are high if detected early, survival rates drop substantially when breast cancer becomes metastatic. The most common sites of metastatic breast cancer are bone, liver and lung. Respiratory viral infections inflict illnesses on countless people. The latest pandemic caused by the respiratory virus, SARS-CoV-2, has infected more than 600 million worldwide, with documented COVID-related death upward of 1 million in the United States alone. Respiratory viral infections result in increased inflammation with immune cell influx and expansion to facilitate viral clearance. Prior studies have shown that inflammation, including through neutrophils, can contribute to dormant cancer cells reawakening and outgrowth. Moreover, inhibition of IL6 has been shown to decrease breast cancer lung metastasis in mouse models. However, how respiratory viral infections contribute to breast cancer lung metastasis remains to be unraveled. Using MMTV/PyMT and MMTV/NEU mouse models of breast cancer lung metastasis and influenza A virus as a model respiratory virus, we demonstrated that acute influenza infection and the accompanying inflammation and immune cell influx awakens and dramatically increased proliferation and expansion of dormant disseminated cancer cells (DCC) in the lungs. Acute influenza infection leads to immune influx and expansion, including neutrophils and macrophages, with increased proportion of MHCII+ macrophages in early time points, and a sustained decrease in CD206+ macrophages starting 6 days post-infection until 28 days after the initial infection. Additionally, we observed a sustained accumulation of CD4+ T cells around expanding tumor cells for as long as 28 days after the infection. Notably, neutrophil depletion or IL6 knockout reversed the flu-induced dormant cell expansion in the lung. Finally, awakened DCC exhibited downregulation of vimentin immunoreactivity, suggesting a role for phenotypic plasticity in DCC outgrowth following viral infection. In conclusion, we show that respiratory viral infections awaken and increase proliferation of dormant breast cancer cells in the lung, and that depletion of neutrophils or blocking IL6 reverses influenza-induced dormant cell awakening and proliferation. Citation Format: Shi Biao Chia, Bryan Johnson, Julio A. Aguirre-Ghiso, Mercedes Rincon, James DeGregori. Pulmonary influenza infection promotes the awakening of dormant metastatic breast cancer cells. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5131.
48
Zhang, Teng, Fangfang Duan, Danhua Su, Long Ma, Jiezuan Yang, Bin Shi, Xiaoyan He, Rui Ma, Suhong Sun та Xinsheng Yao. "Analysis of the Heterogeneity of CD4+CD25+ T Cell TCR β CDR3 Repertoires in Breast Tumor Tissues, Lung Metastatic Tissues, and Spleens from 4T1 Tumor-Bearing BALB/c Mice". Journal of Immunology Research 2020 (24 вересня 2020): 1–21. http://dx.doi.org/10.1155/2020/3184190.
Анотація:
To study the homogeneity and heterogeneity of CD4+CD25+ T cells receptor β-chain complementarity determining region 3 (TCR β CDR3) repertoires in breast tumor tissues, lung metastatic tissues, and spleens from 4T1 tumor-bearing BALB/c mice. We used high-throughput sequencing to analyze the characteristics and changes of CD4+CD25+ TCR β CDR3 repertoires among tumor tissues, lung metastatic tissues, and spleens. The diversity of the CD4+CD25+ TCR β CDR3 repertoires in breast tumor tissue was similar to that of lung metastatic tissues and less pronounced than that of spleen tissues. Breast tumor tissues and lung metastatic tissues had a greater number of high-frequency CDR3 sequences and intermediate-frequency CDR3 sequences than those of spleens. The proportion of unique productive CDR3 sequences in breast tumor tissues and lung metastatic tissues was significantly greater than that in the spleens. The diversity and frequency of the CDR3 repertoires remained homogeneous in breast tumors and lung metastatic tissues and showed great heterogeneity in the spleens, which suggested that the breast tissues and lung metastatic tissues have characteristics of CD4+CD25+ T cells that relate to the tumor microenvironment. However, the number and characteristics of overlapping CDR3 sequences suggested that there were some different CD4+CD25+ T cells in tumors and in the circulatory immune system. The study may be used to further explore the characteristics of the CDR3 repertoires and determine the source of the CD4+CD25+ T cells in the breast cancer microenvironment.
49
Lastrucci, Luciana, Simona Borghesi, Silvia Bertocci, Chiara Gasperi, Andrea Rampini, Giovanna Buonfrate, Paola Pernici, Roberta De Majo, and Pietro Giovanni Gennari. "Advantage of Deep Inspiration Breath Hold in Left-sided Breast Cancer Patients Treated with 3D Conformal Radiotherapy." Tumori Journal 103, no. 1 (September 27, 2016): 72–75. http://dx.doi.org/10.5301/tj.5000563.
Анотація:
Purpose To compare 3D-conformal radiotherapy (3D-CRT) treatment plans based on free-breathing (FB) and deep inspiration breath hold (DIBH) and investigated whether DIBH technique enables a decrease of cardiac left anterior descending coronary artery (LADCA) and lungs dose with respect to the FB. Methods Twenty-three left-sided breast cancer patients referred for breast radiotherapy were included. The planning target volume (PTV) encompassed the breast and organs at risk including heart, LADCA, lungs, and contralateral breast, which were contoured in FB and DIBH CT scans. Dose to PTV was 50 Gy in 25 fractions. Two treatment plans were generated for each patient: FB-3D-CRT and DIBH-3D-CRT. Dosimetry parameters were obtained from dose volume histograms. Data were compared using the paired-sample Wilcoxon signed rank test. Results For heart, LADCA, and left lung, a significant dose reduction was found using DIBH technique. By using DIBH, an average reduction of 25% was observed in LADCA for the volume receiving 20 Gy and of 48% considering the mean heart dose. Conclusions The DIBH technique results in a significant decrease of dose to the heart, LADCA, and left lung compared to FB.
50
Donkor, Michael A., Jamie Choe, Byron Quinn, and Harlan P. Jones. "Abstract A53: Intranasal nanoparticulate PLGA cancer vaccine administration prevents secondary lung metastasis." Cancer Immunology Research 10, no. 12_Supplement (December 1, 2022): A53. http://dx.doi.org/10.1158/2326-6074.tumimm22-a53.
Анотація:
Abstract The lung is one of the most frequent sites of cancer metastasis. Because metastatic lung disease is usually associated with poor survivorship, decreasing secondary lung metastasis will decrease morbidity and mortality associated with cancer. Mitigating tumor immunosurveillance at metastatic sites such as the lung is essential for tumor progression and metastasis. As such, tumors developing elsewhere in the body take advantage of the natural tolerogenicity of the lung to establish immunosuppressive niches via tumor burden induce pre-metastatic niche formation to support lung metastasis. Here we tested the ability of an intranasal nano-vaccine administration to prevent the seeding of tumor cells in the lungs by pre-emptying tumor burden induced immunosuppression. Our hypothesis is that intranasal administration of cancer nano-vaccine will prevent secondary lung metastasis from an existing primary tumor. Because breast cancer is the one of the primary tumors with high propensity to metastasize to the lung, we used the syngeneic mouse breast tumor model to test our hypothesis. Our results showed that intranasal administration of our engineered nano-vaccine protected the lungs of female BALB/c mice from secondary lung metastasis after orthotopic implantation of murine 4T1 tumors. The protection was as a result of nano-vaccine induced antitumor immunity in the lungs. Mice that received the intranasal nano-vaccine had increased frequency of effector T-cells and increase accumulation of lung resident memory T-cell in their lungs. This coincided with increased frequency of IFN-g and granzyme B producing CD8+ T-cells following ex-vivo restimulation of lymphocytes from the lungs of previously immunized mice with tumor cell. These results demonstrate that cancer vaccines can still be part of an integrated cancer therapy where they can be used as a prophylactic approach to prevent secondary lung metastasis. Citation Format: Michael A Donkor, Jamie Choe, Byron Quinn, Harlan P Jones. Intranasal nanoparticulate PLGA cancer vaccine administration prevents secondary lung metastasis [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl):Abstract nr A53.